The U.S. Food and Drug Administration (FDA) has approved Tauklarify (MK-6240), a new brain imaging agent from Lantheus for Alzheimer’s diagnosis. It is used for PET scans to detect tau protein buildup, indicative of Alzheimer’s. Lantheus reported that the drug showed a strong safety profile in trials involving over 1,700 subjects, with less than 1% experiencing adverse reactions. Tauklarify's effectiveness is currently unproven for other brain diseases, and its market competition includes Lilly's Tauvid. Over 7 million people in the U.S. have Alzheimer’s, with projections suggesting that number could exceed 13 million by 2050. Despite this, sales forecasts for Tauklarify are estimated to be under $50 million by 2030.
Fri, 14 Aug 2026 18:51:36 GMT | Radiology Business